Private Capital Group’s Cytokinetics CYTK Stock Holding History

Private Capital Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$19K	Sell	486 -91	-16%	-$3.66K	0.01%	838
2022 Q1	$21K	Sell	577 -11	-2%	-$391	﹤0.01%	1011
2021 Q4	$27K	Hold	588	–	–	0.01%	935
2021 Q3	$21K	Buy	588 +298	+103%	+$8.77K	﹤0.01%	1055
2021 Q2	$6K	Hold	290	–	–	﹤0.01%	1505
2021 Q1	$7K	Buy	+290	New	+$6.19K	﹤0.01%	1391
2019 Q4	–	Sell	-674	Closed	-$8K	–	2017
2019 Q3	$8K	Buy	+674	New	+$8.46K	﹤0.01%	1521

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Private Capital Group's CYTK Position: Q2 2022 in Review

Private Capital Group reduced its Cytokinetics (CYTK) stake by 16% in Q2 2022, selling an estimated $3.66K and leaving 486 shares worth $19K. The position accounts for 0.01% of the portfolio, ranked #838.

Private Capital Group first reported a position in CYTK in Q3 2019 and has held it in 7 quarters since. The position peaked at $27K in Q4 2021. 262 funds tracked by Wall St. Rank hold CYTK as of Q2 2022.

Private Capital Group held 486 shares of Cytokinetics worth $19K as of Q2 2022.
Private Capital Group sold 91 Cytokinetics shares in Q2 2022, an estimated $3.66K.
Cytokinetics made up 0.01% of Private Capital Group's portfolio in Q2 2022, its #838 holding.
Private Capital Group first reported a position in Cytokinetics in Q3 2019 and has held it in 7 quarters since.
Private Capital Group's Cytokinetics position peaked at $27K in Q4 2021.
262 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.